Clinical trial
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell…
NCT00193258 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193258 |
|---|---|
| Title | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma |
| Official title | A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry Novartis |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Erlotinib, Imatinib |
| Enrollment | 94 |
| Start date | Jun 1, 2004 |
| Primary completion | Jan 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 31, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: